Why Bristol-Myers Squibb (BMY) Is Back In The Spotlight

Bristol-Myers Squibb (BMY) is back in focus after a fresh wave of clinical updates, including new oncology data headed to the ESMO 2026 Congress and recent Phase 3 readouts in cancer and pulmonary fibrosis. All this clinical news is landing after a strong run in Bristol-Myers Squibb’s shares this year. The year-to-date share price return of 14.33% and the 1-year total shareholder return of 43.82% indicate momentum that has cooled slightly in recent weeks as traders reassess risk and pipeline...